Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients-Reference-Cited by-同舟云学术

Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients

Published:2024-03-27 Issue:5 Volume:79 Page:1196-1200
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Wu Tzong-Yow¹,Chen Pao-Yu¹²,Wang Jann-Tay¹³,Liu Wang-Da⁴,Chen Yee-Chun¹³⁵^ORCID,Chang Shan-Chwen¹⁵

Affiliation:

1. Department of Internal Medicine, National Taiwan University Hospital , 7 Chung-Shan South Road, Taipei 100 , Taiwan

2. Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine , Taipei , Taiwan

3. National Institutes of Infectious Diseases and Vaccinology, National Health Research Institutes , Zhunan , Taiwan

4. Department of Internal Medicine, National Taiwan University Cancer Center , Taipei , Taiwan

5. School of medicine, National Taiwan University College of Medicine , Taipei , Taiwan

Funder

Ministry of Science and Technology, Taiwan

National Science and Technology Council, Taiwan

Ministry of Health and Welfare

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/jac/article-pdf/79/5/1196/57368083/dkae082.pdf

Reference7 articles.

1. Epidemiological characteristics of the three waves of COVID-19 epidemic in Taiwan during April 2022 to March 2023;Chen;J Formos Med Assoc,2023

2. Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients;Mikulska;Clin Infect Dis,2023

3. Combination therapy with casirivimab/imdevimab and remdesivir for protracted SARS-CoV-2 infection in B-cell-depleted patients;Dioverti;Open Forum Infect Dis,2022

4. Successful treatment of prolonged, severe coronavirus disease 2019 lower respiratory tract disease in a B cell acute lymphoblastic leukemia patient with an extended course of remdesivir and nirmatrelvir/ritonavir;Ford;Clin Infect Dis,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comment on: Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients;Journal of Antimicrobial Chemotherapy;2024-07-29